Filtered By:
Condition: Hemorrhagic Stroke
Therapy: Thrombolytic Therapy
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 340 results found since Jan 2013.
Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
ConclusionsOur case report adds to the evidence that idarucizumab administration is safe in the setting of patients with atrial fibrillation treated with dabigatran who develop acute ischemic stroke requiring thrombolysis.
Source: Journal of Medical Case Reports - August 15, 2017 Category: General Medicine Source Type: research
Increased arterial stiffness is an independent risk factor for hemorrhagic transformation in ischemic stroke undergoing thrombolysis
Hemorrhagic transformation (HT) is a multifactorial phenomenon and represents a possible complication of ischemic stroke, especially after thrombolytic treatment. Increased arterial stiffness has been associated with intracranial hemorrhage, but there is no evidence of association with HT after thrombolytic therapy. The aim of our study is to investigate a possible link between arterial stiffness and HT occurrence after thrombolytic therapy in patients with ischemic stroke.
Source: International Journal of Cardiology - July 23, 2017 Category: Cardiology Authors: Maurizio Acampa, Silvia Camarri, Pietro Enea Lazzerini, Francesca Guideri, Rossana Tassi, Raffaella Valenti, Alessandra Cartocci, Giuseppe Martini Source Type: research
Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke
AbstractTreatment of acute ischemic stroke with the thrombolytic tissue plasminogen activator (tPA) can significantly improve neurological outcomes; however, thrombolytic therapy is associated with an increased risk of intra-cerebral hemorrhage (ICH). Previously, we demonstrated that during stroke tPA acting on the parenchymal side of the neurovascular unit (NVU) can increase blood –brain barrier (BBB) permeability and ICH through activation of latent platelet-derived growth factor-CC (PDGF-CC) and signaling by the PDGF receptor-α (PDGFRα). However, in vitro, activation of PDGF-CC by tPA is very inefficient and the mec...
Source: Acta Neuropathologica - July 19, 2017 Category: Neurology Source Type: research
Thrombolysis for stroke in Ireland: increasing access and maintaining safety in a challenging environment
ConclusionStroke thrombolysis is being effectively and safely provided in acute stroke services in Ireland despite regular involvement of non-specialist staff. There is still potential to improve thrombolysis rate.
Source: Irish Journal of Medical Science - July 17, 2017 Category: General Medicine Source Type: research
Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke
ConclusionIn patients hospitalized with ischaemic stroke, J-shaped, or U-shaped relationships were observed between BP variables and short-term outcomes. However, haemorrhagic complications with thrombolytic therapy were lower with lower BP.
Source: European Heart Journal - June 30, 2017 Category: Cardiology Source Type: research
Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke
AbstractThe blood-brain barrier (BBB) is a vital component of the neurovascular unit (NVU) containing tight junctional (TJ) proteins and different ion and nutrient transporters which maintain normal brain physiology. BBB disruption is a major pathological hallmark in the course of ischemic stroke which is regulated by the actions of different factors working at different stages of cerebral ischemia including matrix metalloproteinases (MMPs), inflammatory modulators, vesicular trafficking, oxidative pathways, and junctional-cytoskeletal interactions. These components interact further to disrupt maintenance of both the parac...
Source: The AAPS Journal - May 8, 2017 Category: Drugs & Pharmacology Source Type: research
Stroke in patients with chronic kidney disease & #8230;: How do we approach and manage it ?
This article is a review of stroke in patients with CKD and approach to managing it.
Source: Indian Journal of Nephrology - May 3, 2017 Category: Urology & Nephrology Authors: S Nayak-Rao MP Shenoy Source Type: research
Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke Research
For ischemic stroke treatment, extension of the therapeutic time window (TTW) of thrombolytic therapy with tissue plasminogen activator (tPA) and amelioration of secondary ischemia/reperfusion (I/R) injury are most desirable. Our previous studies have indicated that liposomal delivery of neuroprotectants into an ischemic region is effective for stroke treatment. In the present study, for solving the above problems in the clinical setting, the usefulness of combination therapy with tPA and liposomal fasudil (fasudil-Lip) was investigated in ischemic stroke model rats with photochemically induced thrombosis, with clots that ...
Source: FASEB Journal - May 1, 2017 Category: Biology Authors: Fukuta, T., Asai, T., Yanagida, Y., Namba, M., Koide, H., Shimizu, K., Oku, N. Tags: Research Source Type: research
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke
Thrombolytic therapy using tissue plasminogen activator (tPA) in acute stroke is associated with increased risks of cerebral hemorrhagic transformation and angioedema. Although plasma kallikrein (PKal) has been implicated in contributing to both hematoma expansion and thrombosis in stroke, its role in the complications associated with the therapeutic use of tPA in stroke is not yet available. We investigated the effects of tPA on plasma prekallikrein (PPK) activation and the role of PKal on cerebral outcomes in a murine thrombotic stroke model treated with tPA. We show that tPA increases PKal activity in vitro in both muri...
Source: Blood - April 20, 2017 Category: Hematology Authors: Simao, F., Ustunkaya, T., Clermont, A. C., Feener, E. P. Tags: Thrombosis and Hemostasis Source Type: research
Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)
Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Barazangi, N., Sorensen, S., Chen, C., Wong, C., Yee, A., Ke, M., Rose, J., Grosvenor, D., Bedenk, A., Fernandes, J., Tong, D. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research
Hemorrhagic transformation of ischemic strokes: risk factors and prognostic implications (P4.291)
Conclusions:IV thrombolytic therapy, cardioembolic stroke and prior warfarin use were independent predictors of HT. PH2 was associated with increased risk of poor outcome at around 90 days and mortality at 90 days and 5 years.Disclosure: Dr. Cheung has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cheung, R., Chan, K. H., Lee, R. Tags: In-Hospital Stroke Care Source Type: research
Acute Stroke Therapy in Infective Endocarditis - Case Series and Systematic Review (P6.295)
Conclusions:Endovascular thrombectomy alone appears to be safer than IV-tPA alone in the management of AIS in patients with IE.Disclosure: Dr. Marquardt has nothing to disclose. Dr. Cho has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Uchino has nothing to disclose. Dr. Wisco has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Marquardt, R., Cho, S.-M., Zhang, L., Uchino, K., Wisco, D. Tags: Cardiovascular Issues in Ischemic Stroke Source Type: research
Parkinsonism or Other Movement Disorders Presenting as Stroke Mimics.
CONCLUSION: Although rare, parkinsonism or other movement disorders may present as a stroke mimic with activation of a stroke code. Consulting neurologists should clarify the etiology for those patients with acute consciousness disturbance or motor weakness and avoid unnecessary thrombolysis. Key Words: Parkinson disease, parkinsonism, movement disorders, stroke code, thrombolysis.
PMID: 28382611 [PubMed - in process]
Source: Acta Neurologica Taiwanica - April 8, 2017 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research
Clinical outcomes of ischemic stroke patients after thrombolytic therapy
Conclusion Thrombolytic therapy presented positive outcomes, regardless of long thrombolysis time and high neurologic deficit scores.
Source: Acta Paulista de Enfermagem - March 24, 2017 Category: Nursing Source Type: research
Angiogram-negative subarachnoid hemorrhage after intravenous thrombolysis in a patient with acute ischemic stroke
We describe a patient with SAH immediately after thrombolytic therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Kyung-Hee Cho, Jae-Gyum Kim, Sungwook Yu, Kyung-Hee Cho Source Type: research
